Analyst picks & changes
Jeffrey Casdin of Oppenheimer & Co. changed his rating on Amgen Inc. to "market performer" from "buy," following publication of the company's fourth quarter earnings. He said the renewed near-term growth of
erythropoietin isn't enough to overcome
